IQVIA Holdings Inc.
IQV · New York Stock Exchange · USD
278,84USD
+7,01 (+2,58 %)Stand 9. Nov., 21:02
Vorbörslich278,01−0,83 (−0,30 %)7:50 ET
Kennzahlen
- Eröffnung
- 274,00
- Vortag
- 271,83
- Tagesspanne
- 270,00 – 279,96
- 52 Wochen
- 154,50 – 284,50
- Volumen
- 1,47 Mio.
- Ø Volumen
- 1,42 Mio.
- Börsenwert
- 45,95 Mrd. $
- KGV
- 33,5
- Gewinn je Aktie (TTM)
- 8,23
- Dividendenrendite
- 0,0 %
- Beta
- 1,2
- Nächste Zahlen
- 4. Feb. 2027
Finanzen
| USD | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Umsatz | 16,31 Mrd. | 15,41 Mrd. | 14,98 Mrd. | 14,41 Mrd. | 13,87 Mrd. |
| Herstellungskosten | 10,88 Mrd. | 10,03 Mrd. | 9,75 Mrd. | 9,38 Mrd. | 9,23 Mrd. |
| Bruttogewinn | 5,43 Mrd. | 5,38 Mrd. | 5,24 Mrd. | 5,03 Mrd. | 4,64 Mrd. |
| Forschung und Entwicklung | 0 | 0 | 0 | 0 | 0 |
| Vertrieb und Verwaltung | 1,99 Mrd. | 1,99 Mrd. | 2,05 Mrd. | 2,07 Mrd. | 1,96 Mrd. |
| Operatives Ergebnis | 2,18 Mrd. | 2,2 Mrd. | 1,98 Mrd. | 1,8 Mrd. | 1,39 Mrd. |
| EBITDA | 2,94 Mrd. | 3,45 Mrd. | 3,26 Mrd. | 2,91 Mrd. | 2,77 Mrd. |
| Nettogewinn | 1,36 Mrd. | 1,37 Mrd. | 1,36 Mrd. | 1,09 Mrd. | 966 Mio. |
| Gewinn je Aktie (verwässert) | 7,84 | 7,49 | 7,29 | 5,72 | 4,95 |
Umsatz nach Segment
Produkte · FY 2025
- Research And Development Solutions8,9 Mrd. $54,54 %+4,33 %
- Technology And Analytics Solutions6,63 Mrd. $40,63 %+7,56 %
- Contract Sales And Medical Solutions788 Mio. $4,83 %+9,75 %
Anteil · ggü. Vorjahr (FY 2024)
Regionen · FY 2025
- Americas7,75 Mrd. $47,49 %+5,29 %
- EMEA5,19 Mrd. $31,79 %+5,39 %
- Asia Pacific3,38 Mrd. $20,72 %+8,02 %
Anteil · ggü. Vorjahr (FY 2024)
Bewertung
Letzte 12 Monate
- KGV
- 33,5
- Kurs-Umsatz-Verhältnis
- 2,7
- Kurs-Buchwert-Verhältnis
- 6,9
- PEG
- 2,5
- Bruttomarge
- 26,5 %
- Operative Marge
- 13,4 %
- Nettomarge
- 8,1 %
- Verschuldungsgrad
- 2,4
- EV/EBITDA
- 16,7
- Eigenkapitalrendite
- 21,8 %
- Kapitalrendite (ROIC)
- 8,2 %
- Free-Cashflow-Rendite
- 4,5 %
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Bruttomarge | 33,3 % | 34,9 % | 35,0 % | 34,9 % | 33,5 % |
| Operative Marge | 13,4 % | 14,3 % | 13,2 % | 12,5 % | 10,0 % |
| Nettomarge | 8,3 % | 8,9 % | 9,1 % | 7,6 % | 7,0 % |
| KGV | 28,5 | 26,0 | 31,3 | 35,2 | 55,9 |
| Kurs-Umsatz-Verhältnis | 2,4 | 2,3 | 2,8 | 2,7 | 3,9 |
| Kurs-Buchwert-Verhältnis | 6,0 | 5,9 | 7,0 | 6,7 | 8,9 |
| Verschuldungsgrad | 2,5 | 2,3 | 2,3 | 2,3 | 2,1 |
| Liquidität 3. Grades | 0,7 | 0,8 | 0,9 | 0,9 | 0,9 |
| Dividendenrendite | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
| Unternehmenswert | 52,94 Mrd. | 48,08 Mrd. | 55,05 Mrd. | 50,23 Mrd. | 65,07 Mrd. |
| EV/EBITDA | 18,0 | 13,9 | 16,9 | 17,3 | 23,5 |
| Eigenkapitalrendite | 20,9 % | 22,6 % | 22,2 % | 18,9 % | 16,0 % |
| Kapitalrendite (ROIC) | 7,9 % | 8,6 % | 8,8 % | 7,3 % | 6,1 % |
| Free-Cashflow-Rendite | 5,3 % | 5,9 % | 3,5 % | 4,1 % | 4,3 % |
Wachstum
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Umsatz | +5,9 % | +2,8 % | +4,0 % | +3,9 % | +22,1 % |
| Bruttogewinn | +1,0 % | +2,6 % | +4,2 % | +8,3 % | +20,3 % |
| Operatives Ergebnis | −0,9 % | +11,4 % | +9,9 % | +29,1 % | +90,6 % |
| Nettogewinn | −0,9 % | +1,1 % | +24,5 % | +12,9 % | +246,2 % |
| Gewinn je Aktie | +4,7 % | +2,7 % | +27,4 % | +15,6 % | +246,2 % |
| Freier Cashflow | −3,0 % | +40,9 % | −5,4 % | −31,1 % | +71,4 % |
| Dividende je Aktie | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
Analysten
Einstufungen · Buy
- 1Stark kaufen
- 36Kaufen
- 7Halten
- 1Verkaufen
- 0Stark verkaufen
Kursziel
289,91
Durchschnitt · +3,97 %
Schätzungen
| FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|
| Umsatz (Ø) | 17,48 Mrd. | 18,55 Mrd. | 19,71 Mrd. |
| Umsatz (Tief – Hoch) | 17,44 Mrd. – 17,54 Mrd. | 18,32 Mrd. – 19,07 Mrd. | 19,26 Mrd. – 20,72 Mrd. |
| Gewinn je Aktie (Ø) | 12,96 | 14,16 | 15,91 |
| Gewinn je Aktie (Tief – Hoch) | 12,94 – 13,00 | 13,49 – 15,22 | 13,67 – 19,06 |
| Analysten | 13 | 13 | 9 |
Letzte Änderungen
- TD Cowen29. Okt. 2026Buy
- JP Morgan28. Okt. 2026Overweight
- Evercore ISI Group28. Okt. 2026Outperform
- Baird28. Okt. 2026Outperform
- Truist Securities28. Okt. 2026Buy
- Stifel14. Okt. 2026Buy
- Mizuho7. Okt. 2026Outperform
- Barclays7. Okt. 2026Overweight
Quartalszahlen
Nächste Zahlen: 4. Feb. 2027| Okt. 2026 | Juli 2026 | Mai 2026 | Feb. 2026 | Okt. 2025 | Juli 2025 | Mai 2025 | Feb. 2025 | |
|---|---|---|---|---|---|---|---|---|
| Gewinn je Aktie · Erwartet | 3,26 | 3,03 | 2,82 | 3,40 | 2,98 | 2,77 | 2,63 | 3,11 |
| Gewinn je Aktie · Tatsächlich | 3,34 | 3,15 | 2,90 | 3,42 | 3,00 | 2,81 | 2,70 | 3,12 |
| Abweichung | +2,45 % | +3,96 % | +2,84 % | +0,59 % | +0,67 % | +1,44 % | +2,66 % | +0,32 % |
| Umsatz · Tatsächlich | 4,43 Mrd. | 4,37 Mrd. | 4,15 Mrd. | 4,36 Mrd. | 4,1 Mrd. | 4,02 Mrd. | 3,83 Mrd. | 3,96 Mrd. |
Dividenden und Splits
Keine Dividenden gezahlt.
Aktiensplits
–
Eigentümer
Institutionen
Q2 2026 · 13F
- Anteil institutioneller Investoren
- 94,02 %
- Investoren mit 13F-Meldung
- 1.123
Größte Investoren
- BLACKROCK, INC.8,70 %14,55 Mio.
- HARRIS ASSOCIATES L P7,29 %12,18 Mio.
- VANGUARD CAPITAL MANAGEMENT LLC6,52 %10,91 Mio.
- VANGUARD PORTFOLIO MANAGEMENT LLC4,49 %7,5 Mio.
- STATE STREET CORP4,46 %7,51 Mio.
- JPMORGAN CHASE & CO3,67 %6,14 Mio.
- ARTISAN PARTNERS LIMITED PARTNERSHIP2,84 %4,74 Mio.
- BOSTON PARTNERS2,67 %4,47 Mio.
Insider-Geschäfte
- Wims Morris Leslie5. Nov. 2026 · directorKauf125 Aktien
- GOGGINS COLLEEN A5. Nov. 2026 · directorKauf144 Aktien
- Fasano Jim5. Nov. 2026 · directorKauf154 Aktien
- DANHAKL JOHN G5. Nov. 2026 · directorKauf134 Aktien
- Berkshire James G.2. Sept. 2026 · officer: See RemarksKauf5381 Aktien · 131,82
- Berkshire James G.2. Sept. 2026 · officer: See RemarksVerkauf2668 Aktien · 261,33
- Berkshire James G.2. Sept. 2026 · officer: See RemarksVerkauf2713 Aktien · 261,54
- Berkshire James G.2. Sept. 2026 · officer: See RemarksVerkauf5381 Aktien · 131,82
Vergleichbare Unternehmen
ALBBYAlibaba Health Information Technology Limited7,5796−1,56 %
CERTCertara, Inc.12,22+1,41 %
CRLCharles River Laboratories International, Inc.353,34+4,69 %
FTREFortrea Holdings Inc.22,24+1,28 %
HCATHealth Catalyst, Inc.1,51+3,42 %
ICLRICON Public Limited Company207,59+1,39 %
MEDPMedpace Holdings, Inc.672,93+3,03 %
MTHRFM3, Inc.10,360,00 %
Über das Unternehmen
IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific. The company's operations are structured into three key divisions: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides a suite of cloud-native applications, complete with implementation services, and offers real-world data solutions designed to empower life sciences and healthcare providers in generating and disseminating evidence crucial for informed decision-making and improving patient outcomes. This division also delivers strategic and operational consulting, including advanced analytics support and outsourcing of commercial processes. Furthermore, it supplies country-level performance metrics detailing pharmaceutical sales, prescribing trends, medical treatments, and promotional activities across diverse channels like retail, hospital, and mail order, with data granularity extending to regional, postal code, and individual prescriber levels. Focusing on clinical trials, the Research & Development Solutions segment offers project management, clinical monitoring, broader clinical trial support, virtual trial capabilities, and strategic planning and design services. It also manages an extensive network of laboratory services, encompassing central, genomic, bioanalytical, ADME, discovery, vaccine, and biomarker analyses. The Contract Sales & Medical Solutions segment is responsible for engaging healthcare professionals and patients, alongside providing scientific strategy and medical affairs support. IQVIA's diverse clientele includes pharmaceutical, biotechnology, medical device and diagnostic, and consumer health companies. The company maintains a strategic collaboration with HealthCore, Inc. Founded in 1982, the firm was formerly known as Quintiles IMS Holdings, Inc. before rebranding as IQVIA Holdings Inc. in November 2017. Its headquarters are located in Durham, North Carolina.
Führung
- Ari BousbibChief Executive Officer & Chairman
- Michael J. FedockExecutive Vice President & Chief Financial Officer
- W. Richard StaubPresident of Research & Development Solutions
- Alistair GrenfellPresident of Commercial Solutions
- Eric SherbetExecutive Vice President, General Counsel & Secretary
- Duane SachsSenior Vice President of Corporate Development
- CEO
- Ari Bousbib
- Mitarbeitende
- 94.000
- Hauptsitz
- Durham, NC, US
- Sektor
- Healthcare
- Branche
- Medical - Diagnostics & Research
- Börsengang
- 9. Mai 2013
- Website
- iqvia.com
Nachrichten
- The Motley Fool · 9. Nov., 20:32IQVIA: 3 Key Takeaways for Long-Term Investors
- Seeking Alpha · 29. Okt., 11:20Artisan Global Value Fund Q3 2026 Portfolio Discussion
- Zacks Investment Research · 29. Okt., 10:51Here's Why IQVIA Holdings (IQV) is a Strong Momentum Stock
- Defense World · 28. Okt., 4:06IQVIA Holdings Inc. $IQV Stock Purchased by Citizens Financial Group Inc. RI
- MarketBeat · 27. Okt., 16:04What IQVIA (IQV) Said on Its Q3 Earnings Call
- Zacks Investment Research · 27. Okt., 11:46IQVIA Holdings Q3 Earnings Beat Estimates, Revenues Increase 8% Y/Y
- Zacks Investment Research · 27. Okt., 9:16IQVIA Holdings (IQV) Surpasses Q3 Earnings and Revenue Estimates
- GuruFocus · 27. Okt., 8:00IQVIA Reports Third-Quarter 2026 Results
- Business Wire · 27. Okt., 7:00IQVIA Reports Third-Quarter 2026 Results
- Zacks Investment Research · 22. Okt., 11:02IQVIA Gears Up to Post Q3 Earnings: Here's What Investors Should Know
Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.